Dyslipidemia, Hypertriglyceridemia
Conditions
Keywords
Hypertriglyceridemia, Dyslipidemia
Brief summary
ZYH7, a novel peroxisome proliferator-activated receptor (PPAR) alpha agonist, is expected to decrease triglyceride level and also correct dyslipidemia.
Interventions
DRUGZYH7
ZYH7 4mg given once orally in the morning before breakfast, for 8 weeks.
DRUGFenofibrate
Fenofibrate 160 mg given once orally in the morning before breakfast, for 8 weeks.
Sponsors
Zydus Lifesciences Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-65 years 2. Subjects of either gender, males or females 3. Triglycerides between 200 to 500 mg/dl on screening visit. 4. Body mass index (BMI) \> 23 kg/m2 5. If subject is diabetic, he should be controlled on a maximum of two oral anti diabetic agents except Thiazolidinedione. 6. Subject has given informed consent for participation in this trial.
Exclusion criteria
1. Pregnancy and lactation. 2. History of 5% weight loss in past 6 months. 3. Subjects on treatment with insulin and PPAR alpha or gamma agonist in the past 3 month. 4. Subjects having unstable angina, acute myocardial infarction in past 3 months or heart failure of New York Heart Association (NYHA) class (III-IV). 5. Uncontrolled hypertension (150/100 mm of Hg).(If Subject using Thiazides, ACE inhibitors, beta blockers they should be on minimum 3 month stable therapy and treatment not expected to change during trial participation) 6. History of clinically significant edema. 7. History of pancreatitis or gall stone diseases. 8. Subject having thyroid-stimulating hormone (TSH) levels outside normal reference range, Subjects who are clinically euthyroid and on stable thyroid replacement therapy for 2 months prior to screening and who are anticipated to remain on this dose throughout the trial period will be allowed. 9. Uncontrolled diabetes (HbA1c ≥ 9 gm %). 10. History of active liver disease or hepatic dysfunction demonstrated by aspartate aminotransferase (AST) and Alanine Aminotransferase(ALT) ≥ 2.5 times of upper normal limit (UNL) or bilirubin ≥ 2 times UNL in the past 3 months. 11. Renal dysfunction demonstrated by abnormal Glomerular Filtration Rate (GFR) (60 ml/min) or presence of ketonuria. 12. History of myopathies or evidence of active muscle diseases demonstrated by Creatinine Phosphokinase(CPK) ≥ 10 times UNL. 13. History of any other concurrent serious illness (e.g. tuberculosis, Human Immunodeficiency Virus(HIV) infection, malignancy, etc). 14. History of alcohol and/or drug abuse. 15. History of known allergy, sensitivity or intolerance to the study drugs and their formulation ingredients. 16. Subjects on any other lipid lowering medications. (Appendix I). 17. If on contraceptive or hormone replacement therapy (HRT), therapy started or changed in last 3 months. 18. Prolonged use of steroids (15 days) in last 3 months (topical preparations, nasal and intra-articular administration are permitted). 19. History of long term use of non-steroidal anti-inflammatory drugs. (1 month) 20. Participation in any other clinical trial in the past 3 months 21. Unable to give informed consent and follow protocol requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage change in mean triglyceride level from baseline | 4 and 8 weeks | Percentage change in mean triglyceride levels from baseline within and across each treatment of ZYH7 The changes will be compared with fenofibrate 160mg. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage change from baseline in lipid parameters | 4 and 8 weeks | Percentage change from baseline in the following lipid parameters: 1. Low Density Lipoprotein Cholesterol(LDL) 2. Very Low Density Lipoprotein Cholesterol (VLDL) 3. High Density Lipoprotein (HDL) 4. Total cholesterol 5. Non HDL Cholesterol (Measured value) 6. Apo A 7. Apo B 8. High sensitive C-Reactive Protein (hs-CRP) |
Countries
India
Outcome results
None listed